Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 1, 2016

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Limbal Stem Cell Deficiency
Interventions
PROCEDURE

Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft

Cultivated autologous limbal epithelial cell (CALEC) therapy utilizes a bio-engineered composite of ex vivo expanded autologous corneal epithelial cells and an FDA-approved amniotic membrane (AmnioGraft®, Bio-Tissue, Inc.) to reconstruct the ocular surface. A small biopsy (2-3 mm2) from the patient's contralateral eye serves as a source epithelial (stem) cells that are expanded on the amniotic membrane in culture and the resulting product is surgically transplanted onto the cornea after excision of the fibrovascular pannus.

BIOLOGICAL

Cultivation of Limbal epithelial cells into a graft

A graft is manufactured for transplant

PROCEDURE

CALEC Transplant

Limbal epithelial cells are obtained from the healthy fellow eye and cultivated in a lab for later transplantation into the diseased eye.

Trial Locations (1)

02114

Massachusetts Eye and Ear Infirmary, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

Massachusetts Eye and Ear Infirmary

OTHER

NCT02592330 - Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft | Biotech Hunter | Biotech Hunter